Wong P C, Chiu A T, Duncia J V, Herblin W F, Smith R D, Timmermans P B
Du Pont Merck Pharmaceutical Company, Experimental Station, Wilmington, DE 19880-0400, USA.
Trends Endocrinol Metab. 1992 Aug;3(6):211-7. doi: 10.1016/1043-2760(92)90030-5.
Recently discovered nonpeptide angiotensin II receptor antagonists represent a new class of potential drugs for the treatment of hypertension and congestive heart failure. Further, these antagonists have been successfully used as selective research tools for physiologic studies of angiotensin H and defining angiotensin II receptor subtypes.
最近发现的非肽类血管紧张素II受体拮抗剂代表了一类用于治疗高血压和充血性心力衰竭的新型潜在药物。此外,这些拮抗剂已成功用作血管紧张素II生理学研究和确定血管紧张素II受体亚型的选择性研究工具。